Essential Laboratory Tests for Chest Pain Evaluation

Initial Laboratory Evaluation

The American College of Cardiology recommends that cardiac troponin (cTn) measurement should be the primary laboratory test for patients presenting with chest pain, with high-sensitivity troponin (hs-cTn) preferred when available, accompanied by an ECG and chest radiograph to evaluate for cardiac and non-cardiac causes 1, 2
Serial cardiac troponin (cTn) I or T levels should be obtained to identify abnormal values and rising/falling patterns indicative of acute myocardial injury 2
High-sensitivity cardiac troponin (hs-cTn) is the preferred biomarker as it enables more rapid detection or exclusion of myocardial injury and increases diagnostic accuracy 2, 3
For patients with suspected ACS, initial troponin should be measured as soon as possible after presentation to the emergency department 1, 4
Serial troponin measurements should follow specific timing protocols: 1-3 hours after initial sample for high-sensitivity assays and 3-6 hours for conventional troponin assays 5

For patients with symptoms that began at least 3 hours before ED arrival, a single hs-cTn concentration below the limit of detection on initial measurement may reasonably exclude myocardial injury 5
Serial troponin measurements are particularly important when clinical suspicion of ACS is high, symptoms persist, or clinical condition deteriorates 1
With high-sensitivity troponin assays, the "rule-out" protocol can be accelerated compared to conventional assays 2

Chest radiograph should be obtained to evaluate for other potential cardiac, pulmonary, and thoracic causes of chest pain 1, 2
With the availability of cardiac troponin, other cardiac biomarkers such as creatine kinase myocardial (CK-MB) isoenzyme and myoglobin are not useful for diagnosis of acute myocardial injury 2

Clinicians should be familiar with the analytical performance and the 99th percentile upper reference limit that defines myocardial injury for the specific troponin assay used at their institution 2
For patients with chest pain and suspected ACS initially evaluated in the office setting, delayed transfer to the ED for troponin or other diagnostic testing should be avoided 4
Previous testing results, when available, should be considered and incorporated into clinical decision pathways 5
Institutions should implement a standardized clinical decision pathway that includes a protocol for troponin sampling based on their particular assay 5

For low-risk patients (30-day risk of death or MACE <1%), discharge without admission or urgent cardiac testing may be reasonable after appropriate troponin evaluation 6
For intermediate-risk patients, additional cardiac testing beyond initial laboratory evaluation may be needed 6
For high-risk patients (including those with new ischemic ECG changes, troponin-confirmed acute myocardial injury, or hemodynamic instability), more aggressive evaluation and management is recommended 7